#United States #Missoula #FYR Bio #Barbara K. Zehentner #EV-Omics

FYR Bio Welcomes New Chief Operating Officer

In an exciting development for the biotechnology sector, FYR Bio has recently appointed Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as its Chief Operating Officer (COO). Known for her extensive background in laboratory operations, Zehentner's expertise is expected to drive the growth of FYR's EV-Omics platform, particularly in the realms of neuroscience and oncology.

A Seasoned Veteran in Laboratory Operations

Zehentner arrives at FYR with more than twenty years of experience managing complex laboratory environments. Her prior roles include significant positions at CareNexa LLC and Adaptive Biotechnologies, where she oversaw large-scale operations and product development. This breadth of experience equips her with the skills necessary to enhance FYR Bio’s offerings and operational capacities.

“I am thrilled to join FYR during such a critical phase,” stated Zehentner. “The approach that FYR is taking with EV-focused multiomics aligns perfectly with my background in scaling sophisticated platforms and improving quality through disciplined execution.”

Strategic Focus on EV-Omics

FYR Bio specializes in utilizing extracellular vesicles (EVs) to derive insights from peripheral blood samples. The company’s EV-Omics platform is designed to provide multiomic data that can improve biomarker discovery, clinical trials, and treatment outcomes. With Zehentner’s guidance, FYR aims to refine its operational strategies, broaden laboratory capacities, and foster stronger partnerships with biopharma and clinical research entities.

CEO and co-founder Chris Booth, PhD, enthusiastically remarked, “Barbara’s proven track record in leading high-complexity laboratory organizations and building efficient teams perfectly positions us for continued growth. As we evolve our platform capabilities, her presence will ensure we maintain the highest standards at every phase.”

Enhancing Partnerships and Capabilities

Under Zehentner's leadership, FYR Bio intends to expand its collaborations, not just limited to biopharma but also with academic institutions. The goal is to create a robust ecosystem that facilitates the rapid development of treatments and enhances patient care through personalized medicine.

Zehentner emphasizes the importance of strengthening compliance and readiness while broadening the laboratory's capacity. “I look forward to leading efforts that enable reliable multiomic outputs, essential for advancing biomarker programs and clinical studies,” she said.

Looking Ahead

As FYR Bio embarks on this new chapter with Barbara K. Zehentner at the helm of operations, anticipation is building around the company's potential to revolutionize the landscape of personalized medicine. With innovative technologies and a focused strategic vision, FYR is well-positioned to make meaningful strides in disease management and treatment efficacy. For more details about their transformative EV-Omics platform, visit fyr.bio.